Research

The efficacy and safety of a new fixed-dose combination of amodiaquine and artesunate in young African children with acute uncomplicated Plasmodium falciparum

Sodiomon B Sirima et al | 16 Mar 2009 | Malaria Journal

Artesunate (AS) plus amodiaquine (AQ) is one artemisinin-based combination (ACT) recommended by the WHO for treating Plasmodium falciparum malaria. Fixed-dose AS/AQ is new, but its safety and efficacy are hitherto untested.

Physical and chemical stability of expired fixed dose combination artemether-lumefantrine in uncontrolled tropical conditions

Roger Bate, Richard Tren, Kimberly Hess & Amir Attaran | 25 Feb 2009 | Malaria Journal

New artemisinin combination therapies pose difficulties of implementation in developing and tropical settings because they have a short shelf-life (two years) relative to the medicines they replace. This limits the reliability and cost of treatment, and the acceptability of this treatment to health care workers. A multi-pronged investigation was made into the chemical and physical stability of fixed dose combination artemether-lumefantrine (FDC-ALU) stored under heterogeneous, uncontrolled African conditions, to probe if a shelf-life extension might be possible.

Household possession, use and non-use of treated or untreated mosquito nets in two ecologically diverse regions of Nigeria - Niger Delta and Sahel Savannah

Bamgboye M. Afolabi et al | 19 Feb 2009 | Malaria Journal

This study found that despite the fact that treated nets were distributed widely across Nigeria, the use of this commodity was still very low in the Sahel Savanna region. Future campaigns should include more purposeful social and health education on the importance and advantages of the use of treated nets to save lives in the Sahel Savannah region of Nigeria.

IMPACT's Impact

Roger Bate & Karen Porter | 29 Jan 2009 | American Enterprise Institute

The World Health Organization (WHO) launched the International Medical Products Anti-Counterfeiting Taskforce (IMPACT) in 2006 to combat the global problem of counterfeit pharmaceuticals, which kill untold thousands of people every year.

Failure of artesunate-mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria in southern Cambodia

William Rogers et al | 12 Jan 2009 | Malaria Journal

Resistance to anti-malarial drugs hampers control efforts and increases the risk of morbidity and mortality from malaria. The efficacy of standard therapies for uncomplicated Plasmodium falciparum and Plasmodium vivax malaria was assessed in Chumkiri, Kampot Province, Cambodia.

Bias & Neglect - Public Health Insecticides & Disease Control

None | 17 Dec 2008 | Africa Fighting Malaria

Insecticides are a vital component of disease control. To a great extent the modern insect-borne disease burden of hundreds of millions of human infections results from failures to use the chemicals we characterize as public health insecticides (PHIs). The modern arsenal of PHIs is antiquated and limited to just 12 insecticides, most belonging to just one class of insecticides (pyrethroids).

Deployment of ACT antimalarials for treatment of malaria: challenges and opportunities

Christopher JM Whitty et al | 11 Dec 2008 | Malaria Journal

Following a long period when the effectiveness of existing mono-therapies for antimalarials was steadily declining with no clear alternative, most malaria-endemic countries in Africa and Asia have adopted artemisinin combination therapy (ACT) as antimalarial drug policy.

Global warming and malaria: knowing the horse before hitching the cart

Paul Reiter | 11 Dec 2008 | Malaria Journal

Speculations on the potential impact of climate change on human health frequently focus on malaria. Predictions are common that in the coming decades, tens - even hundreds - of millions more cases will occur in regions where the disease is already present, and that transmission will extend to higher latitudes and altitudes. Such predictions, sometimes supported by simple models, are persuasive because they are intuitive, but they sidestep factors that are key to the transmission and epidemiology of the disease: the ecology and behaviour of both humans and vectors, and the immunity of the human population.

Integrated vector management for malaria control

John C Beier et al | 11 Dec 2008 | Malaria Journal

Integrated vector management (IVM) is defined as "a rational decision-making process for the optimal use of resources for vector control" and includes five key elements: 1) evidence-based decision-making, 2) integrated approaches 3), collaboration within the health sector and with other sectors, 4) advocacy, social mobilization, and legislation, and 5) capacity-building. In 2004, the WHO adopted IVM globally for the control of all vector-borne diseases. Important recent progress has been made in developing and promoting IVM for national malaria control programmes in Africa at a time when successful malaria control programmes are scaling-up with insecticide-treated nets (ITN) and/or indoor residual spraying (IRS) coverage.

Trends in malaria morbidity following the introduction of artesunate plus amodiaquine combination in M'lomp village dispensary, south-western Senegal

Sophie Sarrassat, Paul Senghor & Jean Yves Le Hesran | 24 Oct 2008 | Malaria Journal

In Thailand, South Africa and Zanzibar, a decrease in malaria morbidity was observed following the introduction of artemisinin-based combination therapy (ACT). In Senegal, therapeutic trials supervised the in vivo efficacy of artesunate plus amodiaquine from 1999 to 2005 at the M'lomp village dispensary. The trends in malaria morbidity in this village were evaluated from 2000 to 2002.